Arrowpoint Investment Partners (Singapore) Pte. Ltd.
Position in ALNY — Alnylam Pharmaceuticals, Inc.
CIK 2032331
SINGAPORE, U0
Position in ALNY
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$1,682,155
+$1,682,155 QoQ
Shares Held
5,588
Ownership
0.004%
of shares outstanding
% of Portfolio
0.51%
of 13F equity value
Holder Rank
#346
of 784 holders
Holding Since
Mar 2025
2 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Derivatives in ALNY
reported options exposure · as of Mar 31, 2025CallValue
$2,052,152
CallShares
7,600
PutValue
$1,728,128
PutShares
6,400
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Jun 30, 2026Arrowpoint Investment Partners (Singapore) Pte. Ltd. holds $37,479,746 across 39 Biotechnology names. ALNY ranks #7 (4.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ARGX |
Argenx SE
|
4,392 | $4,074,765 | |
| 2 | AXSM |
Axsome Therapeutics, Inc.
|
13,831 | $3,385,413 | |
| 3 | INSM |
INSMED Inc
|
30,170 | $3,216,725 | |
| 4 | MDGL |
Madrigal Pharmaceuticals, Inc.
|
5,865 | $3,149,211 | |
| 5 | TVTX |
Travere Therapeutics, Inc.
|
55,112 | $3,130,912 | |
| 6 | PTCT |
Ptc Therapeutics, Inc.
|
36,873 | $3,007,730 | |
| 7 | ALNY |
Alnylam Pharmaceuticals, Inc.
This page
|
5,588 | $1,682,155 | |
| 8 | BMRN |
Biomarin Pharmaceutical Inc
|
27,041 | $1,547,286 |
All Filings in ALNY
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,682,155 | 5,588 | Shares | Defined | 2026-08-13 | |
| 2025-03-31 | $1,728,128 | 6,400 | Put | Defined | 2025-05-13 | |
| 2025-03-31 | $2,052,152 | 7,600 | Call | Defined | 2025-05-13 | |
| No filing history on record for this holder in this stock. | ||||||